BACKGROUND AND AIM: To compare percutaneous transhepatic biliary drainage (PTBD) and endoscopic biliary drainage (EBD) for management of malignant biliary tract obstruction (MBTO). METHODS: PubMed, Google Scholar, and the Cochrane database were searched to 31 December 2013. Main outcome measurements were therapeutic success rate, 30-day mortality rate, overall complications, cholangitis, and pancreatitis. RESULTS: Eight studies (five retrospective and three randomized controlled trials) were included in the meta-analysis with a total of 692 participants. Combined odds ratio (OR) = 2.18 revealed no significant difference in therapeutic success between PTBD and EBD (95% confidence interval [CI] = 0.73-6.47, P = 0.162). However, after excluding two studies that appeared to be outliers, PTBD exhibited a better therapeutic success rate than EBD (pooled OR = 4.45, 95% CI = 2.68-7.40, P < 0.001). Patients who underwent PTBD were 0.55 times as likely to have cholangitis as those who underwent EBD, whereas the overall complication rate, pancreatitis rate, and 30-day mortality were similar between the two procedures. CONCLUSIONS: PTBD may be associated with a better therapeutic success rate and lower incidence of cholangitis than EBD, but the overall complication rate, pancreatitis rate, and 30-day mortality of the two procedures are similar.
BACKGROUND AND AIM: To compare percutaneous transhepatic biliary drainage (PTBD) and endoscopic biliary drainage (EBD) for management of malignant biliary tract obstruction (MBTO). METHODS: PubMed, Google Scholar, and the Cochrane database were searched to 31 December 2013. Main outcome measurements were therapeutic success rate, 30-day mortality rate, overall complications, cholangitis, and pancreatitis. RESULTS: Eight studies (five retrospective and three randomized controlled trials) were included in the meta-analysis with a total of 692 participants. Combined odds ratio (OR) = 2.18 revealed no significant difference in therapeutic success between PTBD and EBD (95% confidence interval [CI] = 0.73-6.47, P = 0.162). However, after excluding two studies that appeared to be outliers, PTBD exhibited a better therapeutic success rate than EBD (pooled OR = 4.45, 95% CI = 2.68-7.40, P < 0.001). Patients who underwent PTBD were 0.55 times as likely to have cholangitis as those who underwent EBD, whereas the overall complication rate, pancreatitis rate, and 30-day mortality were similar between the two procedures. CONCLUSIONS: PTBD may be associated with a better therapeutic success rate and lower incidence of cholangitis than EBD, but the overall complication rate, pancreatitis rate, and 30-day mortality of the two procedures are similar.
Authors: Anne Marie Augustin; Marcus Steingrüber; Friederika Fluck; Oliver Goetze; Thorsten Alexander Bley; Ralph Kickuth Journal: Diagn Interv Radiol Date: 2020-07 Impact factor: 2.630
Authors: Ahmer Hameed; Tony Pang; Judy Chiou; Henry Pleass; Vincent Lam; Michael Hollands; Emma Johnston; Arthur Richardson; Lawrence Yuen Journal: HPB (Oxford) Date: 2016-04-04 Impact factor: 3.647
Authors: Q Lina Hu; Jason B Liu; Ryan J Ellis; Jessica Y Liu; Anthony D Yang; Michael I D'Angelica; Clifford Y Ko; Ryan P Merkow Journal: HPB (Oxford) Date: 2019-07-23 Impact factor: 3.647
Authors: Sebastian Cammann; Kai Timrott; Ralf-Peter Vonberg; Florian W R Vondran; Harald Schrem; Sebastian Suerbaum; Jürgen Klempnauer; Hüseyin Bektas; Moritz Kleine Journal: Langenbecks Arch Surg Date: 2016-05-28 Impact factor: 3.445